News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcon, Inc. (ACL) Completes Acquisition of DUREZOL(TM) and ZYCLORIN(TM) from Sirion Therapeutics


3/30/2010 8:50:16 AM

HUENENBERG, Switzerland--(BUSINESS WIRE)--Alcon (NYSE:ACL), the world’s leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc. Alcon will immediately assume all marketing, promotion and sales of DUREZOL™. Management said that it is continuing to evaluate options to acquire ZIRGAN™, an antiviral recently approved by the FDA for the treatment of acute herpetic keratitis (corneal ulcers).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES